BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30341797)

  • 1. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1.
    Zhou C; Qian W; Ma J; Cheng L; Jiang Z; Yan B; Li J; Duan W; Sun L; Cao J; Wang F; Wu E; Wu Z; Ma Q; Li X
    Cell Prolif; 2019 Jan; 52(1):e12514. PubMed ID: 30341797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
    Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
    Shi Y; Fan Y; Hu Y; Jing J; Wang C; Wu Y; Geng Q; Dong X; Li E; Dong D
    J Cell Mol Med; 2020 Jan; 24(1):760-771. PubMed ID: 31762191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
    Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
    PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
    Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
    Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1.
    Wang Q; Gong M; Liu R; Mo J; Bai R; An R; Wang X; Han L; Wang Z; Ma Q; Wu Z; Zhou C
    Phytomedicine; 2024 Jul; 129():155656. PubMed ID: 38723529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
    Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
    Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
    Wei SH; Dong K; Lin F; Wang X; Li B; Shen JJ; Zhang Q; Wang R; Zhang HZ
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1055-64. PubMed ID: 18297287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
    Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
    Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.
    Yin T; Zhang Z; Cao B; Duan Q; Shi P; Zhao H; Camara SN; Shen Q; Wang C
    Oncotarget; 2016 Jun; 7(24):37192-37204. PubMed ID: 27177084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
    Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
    Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
    Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine.
    Yang MC; Wang HC; Hou YC; Tung HL; Chiu TJ; Shan YS
    Mol Cancer; 2015 Oct; 14():179. PubMed ID: 26458814
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
    Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
    Zou J; Su H; Zou C; Liang X; Fei Z
    J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
    Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
    Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
    Bernhaus A; Ozsvar-Kozma M; Saiko P; Jaschke M; Lackner A; Grusch M; Horvath Z; Madlener S; Krupitza G; Handler N; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
    Invest New Drugs; 2009 Oct; 27(5):393-401. PubMed ID: 18841326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.